Filing Flows › NovoCure (NVCR) › Capital expenditures
NovoCure (NVCR) capital expenditures by quarter
NovoCure's capital expenditures were $6.9M in Q3 2026 (third quarter 2026), +0.1% from Q2 2026. Over the last 3 quarters it ranged from $5.7M (Q3 2025) to $6.9M (Q3 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $6.9M | +0.1% | +22% |
| Q2 2026 | $6.9M | +22% | — |
| Q3 2025 | $5.7M | — | — |
Q3 2026 at a glance
NovoCure, Q3 2026: revenue $193M (+16% year over year), operating margin -3.2%, net loss $10.4M, operating cash flow $22.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is NovoCure's capital expenditures?
NovoCure's capital expenditures were $6.9M in Q3 2026 (third quarter 2026), +0.1% from Q2 2026.
How has NovoCure's capital expenditures changed?
Over the last 3 quarters it ranged from $5.7M (Q3 2025) to $6.9M (Q3 2026).